Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Supply constraints are fully resolved ahead of schedule, enabling rapid global rollout of the obesity franchise.
The $1,465.75 fair value bridges the benchmark gap by correctly weighting forward EPS to capture explicit pipeline momentum.
Eli Lilly's transformation into a metabolic disease juggernaut is yielding an unprecedented hyper-growth phase. Despite massive near-term capital expenditures compressing free cash flow, the underlying margin expansion and forward earnings trajectory support a significantly higher intrinsic value.
Eli Lilly's transformation into a metabolic disease juggernaut is yielding an unprecedented hyper-growth phase. Despite massive near-term capital expenditures compressing free cash flow, the underlying margin expansion and forward earnings trajectory support a significantly higher intrinsic value.
Extensive patent protection on core GLP-1 portfolio.
High clinical inertia and patient reliance on established dosing.
The $1,465.75 fair value bridges the benchmark gap by correctly weighting forward EPS to capture explicit pipeline momentum.
Strong Buy conviction driven by massive TAM expansion and structural duopoly in obesity treatments.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
A severe margin compression event driven by aggressive competitor pricing, early regulatory intervention in obesity treatments, and slower-than-expected capacity expansion. This scenario forces reliance on slower-growth legacy assets.
Intangible assets: Extensive patent protection on core GLP-1 portfolio.
Switching costs: High clinical inertia and patient reliance on established dosing.
Cost advantage: Unprecedented scale in complex biologics manufacturing.
Network effects: Deep entrenchment in physician prescribing workflows.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $22.6B after capex $3.3B, with terminal value at 71.9% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If GLP-1 supply matches demand, revenue beats expectations; if manufacturing bottlenecks persist, near-term estimates will reset lower.
If GLP-1 supply matches demand, revenue beats expectations; if manufacturing bottlenecks persist, near-term estimates will reset lower.
If GLP-1 supply matches demand, revenue beats expectations; if manufacturing bottlenecks persist, near-term estimates will reset lower.
Massive capital expenditure phase to build manufacturing capacity, temporarily suppressing free cash flow.
Unprecedented demand expansion in metabolic diseases, specifically obesity, unlocking massive new TAM.
Political scrutiny on drug pricing and intense generic/biosimilar competition upon patent expiry.
Massive capital expenditure phase to build manufacturing capacity, temporarily suppressing free cash flow.
Core portfolio holding given dominant structural advantage.
Trim exposure if multiple expands past 45x forward EPS or if pipeline momentum severely stalls.
The $1,465.75 fair value bridges the benchmark gap by correctly weighting forward EPS to capture explicit pipeline momentum.
Legacy DCF models over-penalize the necessary transformation capex, creating mispricing.
Strong Buy. The ongoing GLP-1 hyper-scaling justifies the massive capacity investments, paving the way for multi-year compounding.
Downside case: The $1,465.75 fair value bridges the benchmark gap by correctly weighting forward EPS to capture explicit pipeline momentum.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Alternatively, regulatory scrutiny, Medicare negotiation pressures, or unforeseen long-term safety signals severely compress margins and growth.
Medicare aggressively negotiates GLP-1 pricing, capping margins and triggering cascading price cuts across commercial channels.
Unforeseen long-term adverse cardiovascular or gastrointestinal events associated with chronic Mounjaro/Zepbound use surface.
Next-generation oral obesity treatments from competitors demonstrate superior efficacy and tolerability, obliterating the injectable market.
The five developments that would weaken our investment case.
Slowing top-line expansion indicates maturing demand or intensifying market share competition for core incretin therapies, reducing operating leverage and threatening valuation multiples that depend on sustained high-volume adoption.
Current:44.7% for the period ended 2025-12-31
Alert iffalls below 20.0% over any four-quarter period
Severe cost escalation or manufacturing inefficiencies would erode profitability across high-volume production lines, reducing cash generation available for pipeline reinvestment and constraining overall corporate operating margins.
Current:83.0% for the period ended 2025-12-31
Alert ifdrops below 70.0% across any fiscal year
Persistent manufacturing expansion outlays unmatched by top-line gains compress operating profits, signaling unabsorbed fixed overhead and diminishing operational productivity that undermine earnings expansion assumptions.
Current:45.6% for the period ended 2025-12-31
Alert iffalls below 35.0% over any trailing twelve-month period
Aggressive payer concessions and mandatory rebate discounts squeeze net realization per prescription, undermining bottom-line profitability and restricting the capital surplus required for shareholder distributions and balance sheet flexibility.
Current:31.7% for the period ended 2025-12-31
Alert ifdrops below 20.0% in any four-quarter reporting period
Clinical pipeline setbacks or delayed commercial launches strand heavy capital commitments in unapproved candidates, depressing corporate capital efficiency and eroding the economic moat provided by next-generation metabolic franchises.
Current:34.0% as of the report's 2026-05-08 analysis date
Alert ifdecreases below 20.0% over any annual fiscal period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Supply constraints are fully resolved ahead of schedule, enabling rapid global rollout of the obesity franchise. Next-generation oral GLP-1s and pipeline successes in Alzheimer's drive total revenue well past $100B, sustaining a premium valuation multiple.
Eli Lilly is in an unprecedented hyper-growth phase for a mega-cap pharma company, driven by its GLP-1 franchise. With massive revenue expansion, expanding margins, and an aggressive capex build-out to alleviate supply constraints, LLY is fundamentally reshaping the metabolic disease market.
If GLP-1 supply matches demand, revenue beats expectations; if manufacturing bottlenecks persist, near-term estimates will reset lower.
Warning level: falls below 20.0% over any four-quarter period. Slowing top-line expansion indicates maturing demand or intensifying market share competition for core incretin therapies, reducing operating leverage and threatening valuation multiples that depend on sustained high-volume adoption.
Warning level: drops below 70.0% across any fiscal year. Severe cost escalation or manufacturing inefficiencies would erode profitability across high-volume production lines, reducing cash generation available for pipeline reinvestment and constraining overall corporate operating margins.
Warning level: falls below 35.0% over any trailing twelve-month period. Persistent manufacturing expansion outlays unmatched by top-line gains compress operating profits, signaling unabsorbed fixed overhead and diminishing operational productivity that undermine earnings expansion assumptions.
Warning level: drops below 20.0% in any four-quarter reporting period. Aggressive payer concessions and mandatory rebate discounts squeeze net realization per prescription, undermining bottom-line profitability and restricting the capital surplus required for shareholder distributions and balance sheet flexibility.
Warning level: decreases below 20.0% over any annual fiscal period. Clinical pipeline setbacks or delayed commercial launches strand heavy capital commitments in unapproved candidates, depressing corporate capital efficiency and eroding the economic moat provided by next-generation metabolic franchises.
| $28.32B |
| $28.54B |
| $34.12B |
| $45.04B |
| $65.18B |
| +23.2% |
| Gross profit | $21.01B | $21.91B | $27.04B | $36.63B | $54.13B | +26.7% |
| Operating income | $6.36B | $7.14B | $10.33B | $17.04B | $29.70B | +47.0% |
| Net income | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B | +38.7% |
| EPS (diluted) | $6.14 | $6.57 | $5.80 | $11.71 | $22.95 | +39.0% |
| EBITDA | $7.90B | $8.66B | $11.85B | $18.81B | $31.69B | +41.5% |
| R&D | $7.90B | $7.19B | $9.31B | $10.99B | $13.34B | +14.0% |
| SG&A | $6.43B | $6.44B | $7.40B | $8.59B | $11.09B | +14.6% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 65,179,000,000 |
|---|---|
| Cost of revenue | 11,052,000,000 |
| Gross profit | 54,127,000,000 |
| Operating expenses | 24,431,000,000 |
| Operating income | 29,696,000,000 |
| Non-operating items and tax | -9,056,000,000 |
| Net income | 20,640,000,000 |
| Total assets | 112,476,000,000 |
|---|---|
| Cash | 7,268,000,000 |
| Current assets | 55,629,000,000 |
| Total liabilities | 85,941,000,000 |
| Current liabilities | 35,228,000,000 |
| Shareholders’ equity | 26,535,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 28.3B | 7.9B | 5.6B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 22.4% | — | — | — |
| 2022-12-31 | 28.5B | 8.7B | 6.2B | 7.6B | 4.6B | 3B | 1.5B | 371.1M | 1.5B | 3.5B | -62M | — | — | — | — | 2.2B | 16.2B | 29.0% | — | — | — |
| 2023-12-31 | 34.1B | 11.9B | 5.2B | 4.2B | -3.2B | 7.4B | 1.5B | 629M | 750M | 4.1B | 8.7B | — | — | — | — | 2.9B | 25.2B | 30.3% | — | 6.8% | — |
| 2024-12-31 | 45B | 18.8B | 10.6B | 8.8B | 414M | 8.4B | 1.8B | 646M | 2.5B | 4.7B | 8.9B | — | — | — | — | 3.3B | 33.6B | 37.8% | — | 7.9% | — |
| 2025-12-31 | 65.2B | 31.7B | 20.6B | 16.8B | 6B | 10.8B | 2B | 626M | 4.1B | 5.4B | 8.1B | — | — | — | — | 7.3B | 42.5B | 45.6% | — | 7.9% | — |
LLY trades at 22.2x forward earnings against a peer median of 13.9x; EV/EBITDA of 25.1x against a peer median of 13.2x; 6 peers.
| Accumulate below $1,050 level, viewing capex-driven FCF depression as a transient feature. |
| AbbVie Inc. |
| 12.5x |
| 5.7x |
| 14.2x |
| 62.2% |
| 31.6% |
| MRK | Merck & Co. Inc. | 11.8x | 4.2x | 11.0x | 18.9% | 38.6% |
| AMGN | Amgen Inc. | 14.0x | 4.8x | 13.2x | 101.3% | 33.8% |
| GILD | Gilead Sciences Inc. | 13.9x | 5.7x | 12.5x | 40.7% | 37.4% |
